ABOUT
Overview of the project
The project consists of a European-based research structured in 2 different Surveys targeted to patients with metastatic breast cancer with estrogen receptor (ER+) positive disease and oncologists specialized in the care of this condition. Object of the Surveys is to investigate the «Patient and Physician reported preferences». Results of the Surveys will contribute to advancements in the treatment of breast cancer and preparation of scientific publications to improve knowledge in the field.
Breast Cancer
Breast cancer is not a single disease; it encompasses various subtypes, each with distinct characteristics that influence treatment decisions and patients’ journeys. Every year, in Europe, over 550,000 patients are diagnosed with breast cancer. More than 147,000 patients die of this type of cancer in Europe every year. 70% of cases present estrogen-receptor (ER+) positive disease. Beyond its physical toll, breast cancer can have significant socio-economic implications for patients, families, and healthcare systems across Europe. Treatment strategies for breast cancer have advanced significantly in recent years, offering patients a range of options tailored to their specific subtype and individual needs.
Information about centres involved in the project
The Surveys will be addressed to Oncologists and Patients from various centres located in 4 countries in Europe (Italy, Germany, Spain, France) highly specialized in the diagnosis and treatment of breast cancers, identified through the support of Key Opinion Leaders (KOL) from the selected countries. The international approach of the project represents an added value, in terms of sharing expertise from KOLs in different countries.
THE SURVEYS
The two Surveys will employ 1000 Patients and 100 Oncologists, chosen from the 4 selected countries, after given their approval to participation. Each survey consists of various questions, designed for the different target audiences. The topics covered in the Surveys are mainly focused on the approaches and expectations about breast cancer therapeutic pathways.
The Surveys will be delivered to the patients and their physicians through a web-app on their mobile phones.
Main characteristics of the application:
✓ Direct access via a link/QR code
✓ Multilingual contents and services
✓ Project presentation page
✓ No registration form (no data collection from participants)
✓ Mobile-responsive graphics
✓ System for collecting and conducting a statistical analysis of the answers given
STEERING COMMITTEE MEMBERS
Gilles Freyer: Medical Oncology Department, Institut de Cancérologie des HCL, Université de Lyon
Wolfgang Janni – Spokesperson of the AGO: Department of Obstetrics and Gynecology at the University of Ulm – Ulm
Andrea Botticelli: Policlinico Umberto I and la Sapienza University of Rome
Jose Angel Garcia Saenz: Hospital Clínico Universitario San Carlos, Madrid
Julien Peron: Oncology Department, CITOHL, Lyon-Sud Hospital, Cancer Institute of Hospices Civils de Lyon
Michael Untch: Head of the Clinic for Gynecology and Obstetrics, The Dept of Gynecologic Oncology and The Multidisciplinary Breast Cancer Center, Berlin
Saverio Cinieri: Medical Oncology Unit and Breast Unit, Hospital Perrino ASL Brindisi
Angel Guerrero: IVO (Instituto Valenciano de Oncología), Valencia
Thibaut Reverdy: Medical Oncology Department, Institut de Cancérologie des HCL, Université de Lyon
Alessandra Fabi: Director of operational Unit in medical precision in Senology at the IRCCS Policlinico universitario A. Gemelli, Rome
Tatiana Massarrah (nurse): Medical Oncology Research Unit, Hospital Gregorio Marañón, Madrid
Gilles Freyer: Medical Oncology Department, Institut de Cancérologie des HCL, Université de Lyon
Julien Peron: Oncology Department, CITOHL, Lyon-Sud Hospital, Cancer Institute of Hospices Civils de Lyon
Thibaut Reverdy: Medical Oncology Department, Institut de Cancérologie des HCL, Université de Lyon
Wolfgang Janni – Spokesperson of the AGO: Department of Obstetrics and Gynecology at the University of Ulm – Ulm
Michael Untch: Head of the Clinic for Gynecology and Obstetrics, The Dept of Gynecologic Oncology and The Multidisciplinary Breast Cancer Center, Berlin
Andrea Botticelli: Policlinico Umberto I and la Sapienza University of Rome
Saverio Cinieri: Medical Oncology Unit and Breast Unit, Hospital Perrino ASL Brindisi
Alessandra Fabi: Director of operational Unit in medical precision in Senology at the IRCCS Policlinico universitario A. Gemelli, Rome
Jose Angel Garcia Saenz: Hospital Clínico Universitario San Carlos, Madrid
Angel Guerrero: IVO (Instituto Valenciano de Oncología), Valencia
Tatiana Massarrah (nurse): Medical Oncology Research Unit, Hospital Gregorio Marañón, Madrid
RESOURCES
FAQ
The survey is conducted by CD Pharma, in association with relevant oncology centres in 4 European Countries (France, Germany, Italy and Spain) and the support and the patronage of Scientific societies in the various countries. CD Pharma is a consulting service company specialized in supporting and management of projects in the field of pharma.
The purpose of the survey is to understand patients’ and physicians’ preferences in therapeutic management of patients with metastatic breast cancer in follow-up phases.
The data from the surveys will contribute to advancements in the treatment of breast cancer and will be used for preparation of scientific publications to improve knowledge in the field.
Yes, the survey is completely anonymous, and no personal data will be collected.
Yes, the participation to the survey is totally volunteering and no economical compensation is foreseen for the completion of the survey.
Each survey can be completed in 10-15 minutes approximately.
CONTACT INFORMATION
CD Pharma
Via Marghera, 43 – Milano IT
Email: helpdesk@cdpharma.it